NCT06425159: An ongoing trial by Biohaven Therapeutics Ltd.
This trial is ongoing. It must report results 10 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06425159 |
|---|---|
| Title | A Phase 2/3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BHV-7000 as Adjunctive Therapy in Subjects With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures, With Open-label Extension |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 20, 2024 |
| Completion date | March 12, 2026 |
| Required reporting date | March 12, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 29, 2026 |
| Days late | None |